China Strategic Advisory

25 years of China.
360 degrees of
expert coverage.

Fountainhead Global Partners provides 360-degree strategic advice on China — led by a principal with 25 years of legal, political, and commercial experience across China and Hong Kong, and supported by a team of specialists spanning technology, supply chain, regulatory, and national security.

Our Services Our approach
What makes us different
Chinese-language
primary sources
We read what your competitors cannot — patent filings, drug regulator submissions, corporate registry disclosures — in the original language, before they reach English-language analysts.
Legal authority
PRC and Hong Kong
Legal and Political System
Our founding principal brings 25 years of legal dispute and political experience across China and Hong Kong — including front-line engagement as a member of the legislature during the most consequential period in Hong Kong's modern history. Not commentary — counsel.
360-degree coverage
Technology · Supply chain
Policy · National security
Our team of China specialists spans technology, supply chain, regulatory, and national security — covering every dimension of a China-related decision from a single point of contact, rather than requiring clients to assemble and reconcile multiple advisers.
Discover

"China risk does not sit neatly within a single discipline. Neither should the advice."

Fountainhead Global Partners
Boston · New York · London
Who We Are

25 years of China.
360 degrees of
expert coverage.

Fountainhead Global Partners delivers 360-degree strategic advice on China to life sciences corporations, pharmaceutical and biotechnology firms, financial institutions, and investment funds. Our work spans the full spectrum of China risk — political, commercial, technical, and geopolitical — because our clients' decisions rarely sit neatly within a single discipline.

We are led by a principal with 25 years of experience in legal disputes and political engagement across China and Hong Kong — one of the deepest individual track records available in the market. Around that anchor, we have assembled a team of China specialists whose expertise spans technology, supply chain, national security, and regulatory, enabling us to advise on complex, multi-dimensional China questions from a single point of contact.

Our two primary client verticals are life sciences and pharmaceutical — where China's innovation pipeline and regulatory architecture create unique complexity — and financial institutions, where banks, private equity, and hedge funds face an expanding set of China-related counterparty, investment, and regulatory questions that their internal teams are rarely equipped to answer with primary-source rigour.

Primary FocusLife Sciences · Financial Institutions
ScopeChina-related decisions by US and European clients
CoverageOperating across Boston, New York, and London
01
Chinese-Language Intelligence
We access patent databases, corporate registries, drug regulator filings, state investor disclosures, and institutional affiliation records — in the original language. This is not translation. It is analysis that begins where English-only research ends.
02
PRC Legal and Political Authority
Our founding principal brings 25 years of direct engagement with the PRC legal and political system — spanning high-profile commercial disputes, cross-border arbitration, capital markets transactions, and front-line political experience as a member of Hong Kong's legislature. This is not theoretical knowledge of China. It is lived, practitioner-level authority.
03
360-Degree Expert Team
China risk does not respect disciplinary boundaries. Our specialist team covers technology, supply chain, regulatory, and national security — enabling us to give clients a single, integrated assessment across every dimension of a China-related decision, rather than requiring them to assemble multiple advisers and reconcile their findings themselves.
Practice Areas

Six capabilities.
One integrated
practice.

Every Fountainhead capability begins with Chinese-language primary sources. The analysis, legal interpretation, and strategic advice that follow are built on intelligence that clients cannot obtain anywhere else.

Partner & Target Screening

Institutional analysis of Chinese pharmaceutical and biotechnology entities — state ownership mapping, patent co-inventor audits, research institution affiliation screening — from primary sources, in Chinese.

Transaction Due Diligence

Pre-transaction analysis of Chinese counterparties for licensing, M&A, and joint venture transactions — covering ownership structures, state relationships, and regulatory risk invisible to English-language advisers.

Competitive Intelligence

Real-time monitoring of Chinese clinical trial registries, regulatory approvals, patent filings, corporate announcements, and deal activity — translated into competitive and investment intelligence for US and European pharmaceutical companies and financial institutions.

Supply Chain Risk Assessment

Systematic review of Chinese suppliers and service relationships within pharmaceutical supply chains — identifying state ownership structures, national security regulatory exposure, and transition requirements.

Geopolitical Risk Advisory

Scenario analysis and decision-grade briefings on China's regulatory trajectory, technology and supply chain strategy, and the political system factors that shape commercial outcomes — for boards and investment committees.

Executive Briefings

Senior advisory sessions combining PRC legal authority and sector expertise — designed for boards, C-suites, investment committees, and credit and risk committees at financial institutions requiring authoritative China assessment on a specific decision or transaction.

Engagements

Defined scope.
Predictable fees.

Every Fountainhead engagement produces a named deliverable with a defined scope, timeline, and fee. No ambiguity about what you are commissioning or what you will receive.

01
Chinese Partner
Due Diligence
Full institutional due diligence brief on a named Chinese pharmaceutical or biotechnology entity. Covers corporate ownership, state investor identification, patent co-inventor analysis, research institution affiliation screening, and national security regulatory risk. Standard delivery in 10–15 business days; expedited in 5.
02
Executive
Briefing Session
Half-day senior advisory session with Fountainhead's principal team — combining PRC legal authority with technology, supply chain, regulatory, and national security expertise. For boards, investment committees, credit and risk committees, or C-suite teams requiring authoritative China assessment on a specific decision, transaction, or counterparty.
03
China Pharma
Intelligence Bulletin
Quarterly subscription covering Chinese-language monitoring of drug regulator approvals, clinical trial registrations, patent applications, corporate registry changes, and competitive developments across China's pharmaceutical and biotechnology sector.
04
Supply Chain
Risk Audit
Systematic mapping and assessment of Chinese suppliers, equipment providers, and service relationships within a client's pharmaceutical or biotechnology supply chain — with state ownership analysis and a prioritised remediation roadmap.
05
Investment Risk
Assessment
China-specific risk assessment for financial institutions, private equity, and hedge funds evaluating investment exposure to Chinese-linked entities. Covers ownership and control structures, state affiliation, regulatory and political risk, and the specific factors that credit committees and investment committees require documented analysis on before approving China-exposed positions.
06
Strategic Competitive
Advisory
Bespoke mandate for corporations or financial institutions monitoring a specific Chinese entity or sector. Combines ongoing Chinese-language primary source monitoring with periodic analytical briefings on competitive positioning, pipeline developments, regulatory milestones, and ownership changes.
Leadership

Unique credentials.

Founding Principal
Dennis Kwok
Former Member, Hong Kong Legislative Council (2012–2020)
Senior Fellow, Harvard Kennedy School (2021–2023) · Distinguished Scholar, Georgetown SFS (2021) · Northeastern University
Dennis Kwok has spent 25 years at the intersection of law, politics, and commercial life in China and Hong Kong — a depth of experience that is, in practical terms, unreplicable in the Western advisory market.

From 2012 to 2020, Dennis was elected by his peers as the sole representative of the legal profession in the Hong Kong Legislative Council. Whilst in public office, Dennis focused on defending the rule of law, freedom and advancing democracy in Hong Kong.

In recognition for his work in public office, Dennis is the recipient of the New York State Bar Association Award for Distinction in International Law and Affairs 2022, and the Commonwealth Law Conference Rule of Law Award 2021. He was appointed as a Senior Fellow of Harvard Kennedy School, Ash Centre from 2021 to 2023, and as a Distinguished Scholar at Georgetown University School of Foreign Service in 2021. He taught as a visiting Associate Professor at Tokyo University, and is currently a faculty affiliate at the Center for International Affairs and World Culture at Northeastern University.

Dennis has practised law with a focus on the Asia Pacific region for over 25 years. He began his legal career at the international firm Herbert Smith before developing a practice as a barrister in Hong Kong from 2006 to 2023, advising and representing international businesses in complex litigation, arbitration, and cross-border commercial transactions. He was lead counsel in major disputes concerning life sciences and pharmaceutical companies in China and APAC.

He leads a team of China specialists whose collective expertise spans technology, supply chain, national security, and policy — enabling Fountainhead to deliver advice that is genuinely 360 degrees rather than narrow in scope, and is among the most credentialled China authorities available to the private sector.
25 Years Experience PRC Regulatory Capital Markets Life Sciences Disputes
360° Expert Coverage
The
Fountainhead Team
Technology · Supply Chain · Policy · National Security
Chinese-Language Primary Source Analysis
The Fountainhead team covers every dimension of China risk from a single point of contact. Our experts are based across the EU, North America, and Japan — each a leading authority in their field. Together, they span technology assessment, supply chain risk, regulatory analysis, and national security — enabling clients to receive integrated, 360-degree advice rather than disconnected inputs from multiple advisers they must reconcile themselves.

This geographic reach and disciplinary breadth means Fountainhead can mobilise the right expertise for any China-related question, regardless of where the client or the risk sits. Our team members bring deep practitioner experience from government, industry, and academia across three continents.

Underpinning the team's analytical work is a systematic intelligence capability: continuous monitoring and analysis of Chinese patent databases, drug regulator filings, clinical trial registries, corporate registry records, and institutional affiliation databases — in Chinese, before findings reach English-language analysts.
Technology Supply Chain National Security Regulatory Analysis Chinese IP Specialist Chinese-Language Intel
Why Fountainhead

The key questions for any
GC or Risk Committee to ask.

"Who invented this technology — and do any of the inventors have affiliations with state research institutions?"
This requires cross-referencing patent co-inventor records against state and military institution databases — in Chinese, and with a thorough understanding of how the PRC state operates. Fountainhead answers it as a matter of standard methodology.
"Is this Chinese investor a passive fund, or does it carry a state mandate that creates governance risk?"
State investor relationships are often invisible in published corporate materials and obscured through different entities. Fountainhead identifies these relationships routinely through its in-depth knowledge and intelligence in China.
"What is my Chinese competitor filing with regulators that they have not disclosed in English?"
Drug regulator approvals, clinical trial applications, and patent filings are public in Chinese — and almost never monitored systematically by Western intelligence teams. Fountainhead monitors them continuously.
"We are considering a significant investment in a Chinese-linked entity. What does our risk committee actually need to know?"
Credit committees, investment committees, and risk functions at banks and funds increasingly face China-exposure questions that their internal teams are not equipped to answer with primary-source rigour. Fountainhead provides the institutional analysis that gives risk committees the documented basis to decide.
"How does the PRC political system actually shape the regulatory and commercial risk we face?"
Generic commentary cannot answer this with the precision of a legal practitioner with direct PRC dispute and capital markets experience. That is what our founding principal brings.
Get in Touch

Speak with
our team.

Engagements begin with a confidential conversation. Tell us the decision you are facing — we will tell you whether Fountainhead can help and on what timeline.

Coverage
Operating across Boston, New York,
and London
Practice
Life Sciences & Pharmaceutical
Financial Institutions & Investment Funds
Technology & Supply Chain
Discretion
All enquiries are strictly confidential.
We do not disclose client identities.